Organization
Thirty Respiratory Limited
3 clinical trials
Clinical trial
A Randomised Multicentre Post-exposure Prophylaxis Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household MembersStatus: Withdrawn, Estimated PCD: 2022-01-01
Clinical trial
Community Participants With COPD or Bronchiectasis and at Risk of Respiratory Viral Infections Including SARS-CoV-2: An Open-label, Multicentre Feasibility Study of an Inhaled Nitric Oxide Generating Solution (RESP301)Status: Terminated, Estimated PCD: 2022-12-22
Clinical trial
A Phase 2 Study to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2024-04-30